Welcome to our dedicated page for Kymera Therapeutics SEC filings (Ticker: KYMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kymera Therapeutics filings document the regulatory record of a Nasdaq-listed clinical-stage biotechnology company developing oral small molecule degraders through targeted protein degradation. Its Form 8-K reports cover material events such as operating and financial results, clinical and regulatory disclosures, Regulation FD presentations, collaboration-related updates, and capital-raising arrangements involving common stock.
Proxy and governance filings describe shareholder voting matters, executive compensation, equity awards, board oversight, and bylaw provisions, including forum-selection language. The filing record also identifies KYMR common stock and recurring disclosure areas tied to the company’s pipeline, financing capacity, corporate governance, and public-company reporting obligations.
Kymera Therapeutics Chief Operating Officer Jeremy G. Chadwick reported option exercises and related share sales. On April 14–15, 2026, he exercised stock options to acquire a total of 6,551 shares of common stock at exercise prices of $30.17 and $43.50 per share.
On the same dates, he sold 6,551 common shares in open-market transactions at prices around $90.00 to $90.10 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly owned 61,202 Kymera Therapeutics shares.
Kymera Therapeutics director Bruce Booth reported option exercises and share sales in Kymera Therapeutics, Inc. common stock. Booth exercised stock options to acquire 6,359 shares at an exercise price of $14.18 per share, then sold 6,359 directly held shares in open-market trades around $90 per share.
Additional sales of 2,750 shares and 385 shares were made by investment funds Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P., with which Booth is associated and where he disclaims Section 16 beneficial ownership except for any pecuniary interest. These transactions, totaling 9,494 shares sold, were executed under Rule 10b5-1 trading plans adopted in December 2025, indicating they were pre-arranged rather than timed discretionarily.
KYMR and certain holders submitted Form 144 to notify proposed sales of Common Stock. The filing lists specific proposed sales by Atlas Venture Fund X (71,814 shares for $6,472,674.74), Atlas Venture Opportunity Fund I (10,052 shares for $905,997.81), and Bruce Booth (4,159 shares for $374,199.56), with a filing reference date of 04/15/2026.
KYMR submitted Form 144 notifications disclosing proposed sales of Common Stock by selling holders. The excerpt lists three recent proposed transactions: Atlas Venture Fund X, L.P. proposes 71,814 shares (proceeds $6,472,674.74), Atlas Venture Opportunity Fund I, L.P. proposes 10,052 shares (proceeds $905,997.81), and Bruce Booth proposes 4,159 shares (proceeds $374,199.56), with dates shown in March–April 2026.
KYMR reported a Form 144 notifying the proposed sale of 1,300 shares tied to an exercise of stock options for cash on 04/15/2026. The filing also lists multiple 10b5-1 sales by Jeremy Chadwick in March–April 2026, including large trades such as 91,250 shares on 03/23/2026.
KYMR submitted a Form 144 notice reporting an intended sale of 24,000 shares of Common Stock by Merrill Lynch, with the filing dated 04/14/2026. The notice lists two stock option items of 12,000 shares each and shows recent dispositions by Atlas Venture entities on 03/02/2026.
KYMR insider sale disclosed under Rule 144. The filing reports an intended sale of 5,251 shares of Common Stock on 04/14/2026 via an exercise-of-stock-options cash transaction. The filing also lists multiple prior 10b5-1 sales in March and April 2026, including 91,250 shares sold on 03/23/2026 for $7,063,733.26.
Kymera Therapeutics Chief Business Officer Noah Goodman exercised stock options and sold shares in a planned series of transactions. On April 9, he exercised options to acquire 2,500 shares of common stock at an exercise price of $21.05 per share and continued to hold 97,500 options afterward. He then sold a total of 10,264 shares of common stock on April 9 and 10 in open-market transactions at weighted average prices around the mid-$80s to high-$80s. Footnotes state that some shares were sold automatically to cover tax withholding on vested RSUs and that the trades were made under a Rule 10b5-1 trading plan dated December 10, 2025. Following these transactions, he directly holds 51,542.438 shares of Kymera common stock.
Kymera Therapeutics, Inc. filed a Form 144 to sell shares on 04/09/2026. The notice lists 9,111 shares described as shares acquired upon vesting of Restricted Stock Units under the 2020 Equity Incentive Plan and 2,500 shares from exercise of stock options; sales are through Morgan Stanley Smith Barney LLC.
Kymera Therapeutics director Elena Ridloff exercised stock options covering 12,000 shares of common stock at an exercise price of $14.18 per share, then sold 12,000 shares in open-market transactions at weighted average prices around $85–$86 under a pre-arranged Rule 10b5-1 trading plan, leaving no directly held common shares reported.